The quantifying graphs are new, the correlation with amounts is not. It's simply been quantified to a greater degree. Look at Dr. Bosch's presentation at ASCO from 16:00 all the way to 17:00. It is all three. IL-6, IL-8 and TNF-a. They are maturing/activating /selecting for DCs that can produce these cytokines at high levels.
Now go to 20:30 seconds to 21:15. If they activate/mature the DCs right, they get DCs that will produce high amounts of TNF-a, il-8 and il-6.
If you listen to LP, and look at the more recent poster from September 16, you will see again that it is all 3 cytokines that are predictive of response.
Again, this is method B activation/maturation, because we know Dr. Bosch will no longer use method A.
It may be, because there are 4 different quantities ranges for TNF-a (ng/10 to the 6th cells/24 hours) on the survival chart from September 2016 that they now understand they actually have to get DCs matured producing over 130 ng/10 to the 6th/24 hours. Kind of a super method b, if you will.
I'm not certain why you are hung up on IL-8 exclusively. Both Dr. Bosch and LP state it is all three cytokines. This is what they are selecting for, and now they know they must even select higher for TNF-a prior to freezing the DCs into aliquots for later thawing and injection.
What you are suggesting is that they can only achieve method B, or I might call "super method B" dendritic cells in some patients' DCs.
I don't think that is what LP was saying at all. I think when they correctly mature and select, they can obtain/manufacture these DCs.
So all patients can get that level of Dendritic Cell. Il-8 over 1000 ng/10 to the 6th/24 hours, TNF-a over 130 ng/10 to the 6th/24 hours aka: super method B and Il-6 above some range we have not been given.
It is after these DCs are injected in the body that we can then see it working on both people who could and even those who could not previously achieve an immune response.
The only thing about IL-8 that LP mentioned is unexpected, is that normally scientists think IL-8 will produce/prognosticate poor outcome, however, that is not the case here. Again, I am saying that the fact DCVax works particularly well against mesenchymal cells probably explains this, because il-8 actually signals for epithelial (neural) to mesenchymal transition. Thus, for many, that would mean a less manageable cancer because mesencyhymal are so aggressive, but for DCVax, transitioning cells to that state makes them more vulnerable to DCVax-Direct, the other cytokines and the consequent t-cell attack brought on by DCVax-Direct t-cell signaling after DC migration (and/or perhaps some intratumoral communication.)
News 
Market Data 
Discover 
